Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02684565
Other study ID # IRB#15-001928
Secondary ID
Status Completed
Phase N/A
First received February 9, 2016
Last updated February 8, 2018
Start date October 2016
Est. completion date February 2018

Study information

Verified date February 2018
Source University of California, Los Angeles
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Branching chain amino acids (BCAA) have both beneficial and detrimental effects of on metabolism have been established and therefore warrants further investigation. In the preliminary study, the investigators found that BCAAs enhanced glucose metabolism in lean mice while they promoted glucose intolerance in obese mice. In lean mice, BCAAs decreased adiposity and enhanced glucose utilization and insulin sensitivity in different tissues. But in obese mice, BCAAs' effects were mediated by impaired insulin signaling in fat tissue.

This study will examine 10 obese subjects with pre-diabetes and examine the effects of taking BCAA supplement and will monitor the subjects blood glucose, insulin, triglyceride levels and will have an oral glucose tolerance test on repeated occasions to see if any changes are noted in their glucose regulation.


Description:

Branched-Chain Amino Acids (BCAAs, including leucine, isoleucine, and valine) regulate multiple cellular functions as nutrient signaling. For example, BCAAs regulate insulin and glucagon secretion and thus glucose metabolism1. BCAAs, especially leucine, is one key regulator of mTOR signaling, which is the central component of a complex signaling network of insulin signaling, cell growth, and proliferation. BCAAs also regulate protein synthesis and degradation in various tissues.

Increasing dietary uptake of BCAAs improved the parameters associated with obesity and T2DM, such as body composition and glycemia levels. However, these beneficial effects are not conclusive. Moreover, other studies have shown that circulating branched-chain amino acid concentrations are associated with obesity and future insulin resistance in children and adolescents.

This is a 12-week, randomized, crossover study with 10 obese subjects with prediabetes. Subjects will be randomly assigned to take 20g BCAA or low-BCAA protein a day for 4 weeks, then switch to BCAA or low-BCAA protein for 4 weeks after a 2-week washout.

At baseline and weeks 4, 6 and 10 weeks glucose, insulin and triglyceride levels will be tested at time 0, 30 min, 60 min, and 120 min after 75 grams of glucose load. In addition to laboratory tests vital signs, weight and body composition will be done.


Recruitment information / eligibility

Status Completed
Enrollment 11
Est. completion date February 2018
Est. primary completion date February 2018
Accepts healthy volunteers No
Gender All
Age group 20 Years to 50 Years
Eligibility Inclusion Criteria:

1. Age 20-50 years of age at screen

2. BMI between 27 to 35

3. Fasting glucose level >100, but <126 mg/dL or HgbA1c >5.7% but < 6.4%

4. Waist circumference > 40 cm in men and >35 in women

5. Subjects must read and sign the Institutional Review Board-approved written informed consent prior to the initiation of any study specific procedures or enrollment. A subject will be excluded for any condition that might compromise the ability to give truly informed consent.

Exclusion Criteria:

1. Any subject with a history of diabetes mellitus on medications, or other serious medical condition, such as chronic hepatic or renal disease, bleeding disorder, congestive heart disease, cancer (except skin basal cell carcinoma ) chronic diarrhea disorders, myocardial infarction, coronary artery bypass graft, angioplasty within 6 months prior to screening, current diagnosis of uncontrolled hypertension (defined as systolic BP>160mmHg, diastolic BP>95mmHg), active or chronic gastrointestinal disorders, bulimia, anorexia, or endocrine diseases (except thyroid disease requiring medication) as indicated by medical history or routine physical examination.

2. Any subject with a screening laboratory value outside of the laboratory normal range that is considered clinically significant for study participation by the investigator.

3. Any subject who currently uses tobacco products.

4. Any history of gastrointestinal disease except for appendectomy.

5. Any antibiotic or laxative use during the 2 months before the study.

6. Any subject who is unable or unwilling to comply with the study protocol.

7. Any subject allergic to soy products.

Study Design


Related Conditions & MeSH terms


Intervention

Dietary Supplement:
BCAA High Protein supplement
Subjects will be randomly assigned to take high BCAA or low-BCAA protein a day for 4 weeks, then switch to BCAA or low-BCAA protein for 4 weeks after a 2-week washout.
BCAA Low Protein supplement
Subjects will be randomly assigned to take high BCAA or low-BCAA protein a day for 4 weeks, then switch to BCAA or low-BCAA protein for 4 weeks after a 2-week washout.

Locations

Country Name City State
United States University of California, Los Angeles Los Angeles California

Sponsors (1)

Lead Sponsor Collaborator
University of California, Los Angeles

Country where clinical trial is conducted

United States, 

References & Publications (3)

Lynch CJ, Adams SH. Branched-chain amino acids in metabolic signalling and insulin resistance. Nat Rev Endocrinol. 2014 Dec;10(12):723-36. doi: 10.1038/nrendo.2014.171. Epub 2014 Oct 7. Review. — View Citation

McCormack SE, Shaham O, McCarthy MA, Deik AA, Wang TJ, Gerszten RE, Clish CB, Mootha VK, Grinspoon SK, Fleischman A. Circulating branched-chain amino acid concentrations are associated with obesity and future insulin resistance in children and adolescents. Pediatr Obes. 2013 Feb;8(1):52-61. doi: 10.1111/j.2047-6310.2012.00087.x. Epub 2012 Sep 7. — View Citation

Pal S, Ellis V. The acute effects of four protein meals on insulin, glucose, appetite and energy intake in lean men. Br J Nutr. 2010 Oct;104(8):1241-8. doi: 10.1017/S0007114510001911. Epub 2010 May 11. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Change in glucose tolerance composition that Are Related to High protein BCAA Treatment The major changes in glucose tolerance after taking supplement Baseline to 4 weeks
Primary Change in glucose tolerance and body composition that Are Related to Low protein BCAA Treatment The major changes in glucose tolerance after taking supplement Baseline to 4 weeks
Secondary Change in glucose tolerance and body composition that Are Related to Low protein BCAA treament Change in body composition after taking supplement baseline to 4 weeks
Secondary Change in glucose tolerance and body composition that Are Related to High Protein BCAA treament Change in body composition after taking supplement Baseline to 4 weeks
See also
  Status Clinical Trial Phase
Completed NCT05424107 - A Mediterranean Intervention on Prediabetic Children N/A
Recruiting NCT02681887 - Effect of Melatonin on Cardiometabolic Risk- FULL Phase 3
Completed NCT04088461 - Effect of Linagliptin + Metformin on Patients Who do Not Achieve Normoglucemia With Metformine Phase 4
Recruiting NCT02561377 - Effect of Resistance Training on Metabolic Control and Outcome in Prediabetes (NMR-based Metabonomics) N/A
Completed NCT02678390 - Medium Chain Triglycerides and Aerobic Exercise on Ketone Production in Women With or Without Prediabetes N/A
Completed NCT02551640 - Improving Physical Activity Through a mHealth Intervention in Cardio-metabolic Risk Patients N/A
Completed NCT02459691 - Culturally-adapted Diabetes Prevention Lifestyle Intervention for Latinos (E-LITE Latinos) N/A
Completed NCT01479933 - Glucose Metabolism Effects of Vitamin D Supplementation in Prediabetes N/A
Completed NCT01671293 - Multicomponent Telecare Model for Supporting Prediabetes Patients N/A
Completed NCT00960973 - The Effect of Vitamin K Supplementation on Glucose Metabolism Phase 4
Completed NCT00455325 - Chloroquine to Treat People With Metabolic Syndrome Aim2 (ARCH-MS) Phase 2
Recruiting NCT05123963 - Restoring 24-hour Substrate Rhythmicity to Improve Glycemic Control by Timing of Lifestyle Factors N/A
Recruiting NCT05340868 - Genetics of the Acute Response to Oral Semaglutide N/A
Recruiting NCT04984421 - IMplementation of the Family Support PRogramme A Healthy School Start to Prevent OVErweight and Obesity (IMPROVE) N/A
Recruiting NCT04131582 - Effect of Empagliflozin + Linagliptin + Metformin + Lifestyle in Patients With Prediabetes Phase 3
Recruiting NCT04134650 - Effect of Low Dose Combination of Linagliptin + Metformin to Prevent Diabetes Phase 3
Recruiting NCT05347030 - Acupuncture for Impaired Glucose Tolerance in Overweight/Obese Population N/A
Completed NCT04074148 - Effectiveness of Diabetes Prevention Education Program on Diabetes Prevention Among Prediabetes Population in Nepal N/A
Recruiting NCT05050266 - Enhancing Mental and Physical Health of Women Veterans N/A
Completed NCT01956929 - Metformin's Effect on Glucagon-induced Glucose Production and Protein Metabolism. Phase 1